19:49 , Jun 7, 2019 |  BioCentury  |  Emerging Company Profile

insitro: machine learning with designated data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a...
23:49 , Jun 6, 2019 |  BC Extra  |  Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

Grail Inc. (Menlo Park, Calif.) hired Hans Bishop as CEO to succeed Jennifer Cook, who also stepped down from the cancer diagnostic company's board, citing family health reasons. Bishop, who has been on Grail’s board...
23:58 , Jun 5, 2019 |  BC Extra  |  Company News

Management tracks: Settleman to lead Pfizer cancer R&D; plus Roivant, LabCorp and more

Pfizer Inc. (NYSE:PFE) hired Jeff Settleman as SVP and group head of oncology R&D, effective July 1. He was head of oncology research at Calico Life Sciences LLC (South San Francisco, Calif.) and prior to...
23:25 , May 6, 2019 |  BC Innovations  |  Translation in Brief

Baby brain organoids link stress response to hypoxic encephalopathy

Brain organoids could help unravel one complication of extremely premature birth: hypoxic encephalopathy. A Stanford group used the technology to zero in on the unfolded protein response as a target for preventing the indication. Encephalopathy...
12:21 , Apr 16, 2019 |  BC Extra  |  Company News

With insitro deal, Gilead turns to machine learning to unlock new NASH targets

Not yet content with the trio of clinical programs in its pipeline, Gilead has struck its third NASH deal this year, this time banking on machine learning company insitro to develop disease models and discover...
23:01 , Jan 31, 2019 |  BC Extra  |  Company News

Management tracks: Calico, Apellis, Immutep

Calico Life Sciences LLC (South San Francisco, Calif.) hired Aarif Khakoo as its first head of drug development. He will lead the company’s early stage development from candidate selection through Phase II. Khakoo was VP...
18:45 , Nov 9, 2018 |  BC Week In Review  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
22:27 , Nov 2, 2018 |  BC Extra  |  Company News

AbbVie gains Parkinson’s pipeline from BioArctic

AbbVie Inc. (NYSE:ABBV) gained exclusive, worldwide rights to a pipeline of antibodies targeting α-synuclein (SNCA) to treat Parkinson’s disease for $50 million through an option exercise with BioArctic AB (SSE:BIOA B). The deal is valued...
23:15 , Oct 26, 2018 |  BioCentury  |  Product Development

R&D merry-go-round

An exodus of pharma R&D leaders to small biotechs and start-ups over the last year reflects a new phase in the ecosystem’s churn of talent. But it’s not all loss for the pharmas. The transition...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...